



November 30, 2021

Whom It May Concern

Company: KYORIN Holdings, Inc.
Representative: Yutaka Ogihara
Representative Director, President
(Security Code: 4569, TSE 1st Sec.)
Contact: Yoshinori Tanifuji
Director, Management Strategy &
Planning Division Corporate Planning
Telephone: +81-3-3525-4707

Launch of “Compact Real Time PCR System GeneSoC® mini”

KYORIN Pharmaceutical Co., Ltd. (head office: Chiyoda-ku, Tokyo; President and CEO: Shigeru Ogihara, “KYORIN Pharmaceutical”), which is a subsidiary of KYORIN Holdings, Inc., launched the "Compact Real Time PCR System GeneSoC® mini" (hereinafter “the device”) today.

The device can identify the target gene in a sample in a short time (about 5-15 minutes) by the original microfluidic thermal cycle technology based on the real-time PCR *1 and is lightweight and compact, and can be installed in a limited space.

By realizing the high speed and miniaturization of the device, it will contribute to clinical examination as a POCT* 2.

KYORIN Pharmaceutical aims to develop and launch research reagents and in-vitro diagnostics for “GeneSoC®” and the device and will contribute to the diagnosis, prevention, and treatment of infectious diseases through these products.

The impact of the launch of the device on KYORIN Holdings’ consolidated operating results for the fiscal year ending March 31, 2022 is minor.

- ※1 PCR (Polymerase Chain Reaction) : Technique used to amplify a gene
※2 POCT (Point of Care Testing) : Testing carried out by healthcare professionals at the patient’s side

“Compact Real Time PCR System GeneSoC® mini” Product Outline

- Product Name: “Compact Real Time PCR System GeneSoC® mini”
- Price (including tablet) : 1,152,800 yen (with tax)
- Dimension: Top surface about $\Phi 86\text{mm} \times$
Bottom surface about $\Phi 105\text{mm} \times$ Height about 155mm
- Weight: About 650g (excluding AC adaptor)
- Manufacture and sale notification No.: 13B3X10244000001

